Weight loss drugs: Scaling up

Weight loss drugs have pushed the obesity therapeutics market to an inflection point, reshaping not only patient behaviour, healthcare spending and investor expectations, but also potentially the global economic outlook, as lower obesity rates could promise higher productivity and reduced long term healthcare costs.

In this episode of the Barclays Brief, Patrick Coffey speaks with Emily Field, Head of US Biopharmaceuticals Equity Research, to break down the forces driving this shift.

They pinpoint the key accelerants: the arrival of oral versions, rapid uptake among consumers, shifting cash‑pay models, intensifying pricing pressure, and fierce competition facing the early leaders.

At the core, the episode answers this question: as these medicines move from specialist treatments to mass‑market consumer products, how will they reshape the market and determine who wins economically?

They also look ahead to the sector’s next phase, from ex‑US adoption and earnings signals to new entrants, combination therapies and future applications in areas such as addiction.

Clients can read more on Barclays Live:

• There’s no place like home; initiating coverage on U.S. Biopharmaceuticals

• Brave New World: Goodbye MFN, Hello Pipeline

• Protein Boom: Be prepared…

Survey source: KFF Health Tracking Poll

Important Content Disclosures

Important non-Research Content Disclosures

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(33)

Forces shaping markets in 2026

Most episodes of The Barclays Brief focus on a single market theme, but this week we have a special episode for you. Adeel Khan, our Global Head of Markets, joined hosts Ronnie Wexler and Patrick Coff...

28 Tammi 13min

Rise of the humanoid robots

Humanoid robotics is moving from experimentation and into a true economic inflection point. The market, valued at just $2–3bn today, is projected to expand to ~$40bn by 2035 in the base case*, with up...

20 Tammi 12min

Headlines to hedges: Positioning in 2026

In just the first two weeks of 2026, investors have had a lot to take in amidst fast-moving headlines and shifting policy signals.In this episode of Barclays Brief, Global Head of Macro Distribution ...

13 Tammi 11min

AI: The macro game changer

While traditional macroeconomic factors such as labour markets, central bank policy and inflation are all important considerations for 2026, the economy is “going to live or die” by what happens with ...

6 Tammi 10min

Robotaxis: The future of mobility

2026 is expected to be a breakthrough year for the US robotaxi market, as autonomous vehicles shift gears from pilot projects to large-scale deployment across major cities.Some players are expanding t...

22 Joulu 202512min

Credit markets: What's ahead for 2026

If you spent 2025 watching credit and thinking “this feels suspiciously quiet,” you are not alone. Barclays’ Global Head of Research, Brad Rogoff, and Global Head of Equities Distribution, Ronnie Wexl...

16 Joulu 20259min

Seismic Shifts: Agentic AI in Energy

Conversations about AI often revolve around the outlooks for the Mag7, capex or the resources required to power the technology. This episode of the Barclays Brief explores agentic AI’s potential for t...

9 Joulu 202510min

Is the stock market actually the economy now?

The rise of real-time trading platforms, combined with steady 401(k) inflows, has amplified wealth effects – making retail investors acutely aware that fluctuations in equity markets directly influenc...

2 Joulu 202510min